{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:12:05Z","timestamp":1654564325494},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The BCL2 inhibitor venetoclax is approved in the United States for only a subset of patients with refractory chronic lymphocytic leukemia. However, in light of data presented at the American Society of Hematology 2017 Annual Meeting, clinicians are thinking ahead to administering the drug more broadly\u2014in combinations and as a first-line therapy\u2014for other patients with the disease.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nd2018-003","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T01:30:20Z","timestamp":1517362220000},"page":"OF5-OF5","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax Data Prompt Rethink of CLL Therapy"],"prefix":"10.1158","volume":"8","member":"1086","published-online":{"date-parts":[[2018,3,1]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/3\/OF5\/6125\/Venetoclax-Data-Prompt-Rethink-of-CLL","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/3\/OF5\/6125\/Venetoclax-Data-Prompt-Rethink-of-CLL","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:54:46Z","timestamp":1654563286000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/3\/OF5\/6125\/Venetoclax-Data-Prompt-Rethink-of-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nd2018-003","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]}}}